Incyte

United Therapeutics

Gilead Sciences

Natera

Alnylam Pharmaceuticals

Neurocrine Biosciences

Vertex Pharmaceuticals

Amgen

Insmed

Sarepta Therapeutics

SPDR S&P Biotech ETF

XBI tracks an equal-weighted index of US biotechnology stocks.

Global X MSCI Colombia ETF

iShares 20+ Year Treasury Bond ETF

The global economy faces significant uncertainty. High-interest rates, persistent inflation and geopolitical crises all threaten to roil financial markets.

Don't Miss the Boom: 3 ETFs Set to Explode Higher

First Trust NASDAQ Clean Edge Smart Grid Infrastructure Index Fund

Janus Henderson Small Cap Growth Alpha ETF

 Invesco S&P SmallCap Consumer Discretionary ETF

SPDR S&P Semiconductor ETF

The beaten-down prices offer a solid buying opportunity for investors. We have highlighted five ETFs from different corners that have declined over the past three months but have a solid Zacks ETF Rank #1 (Strong Buy) or 2 (Buy).

5 Beaten-Down ETFs to Buy Now

abrdn Healthcare Investors 

iShares Nasdaq Biotechnology ETF

Illumina

IQVIA Hlds

Direxion Daily S&P Biotech Bull 3X Shares

Lonza Group AG

Merck

Navistar

Omega Healthcare Investors

Pfizer

Royalty Pharma

abrdn World Healthcare Fund 

Wuxi Biologics Cayman Inc

Health Care Select Sector SPDR Fund

The recent IRA list of 10 drug publications is not expected to have a significant impact on big pharma stocks in the near term. The legal challenges by big pharma companies against the IRA may derail the implementation of the drug pricing reforms. Investors can consider diversified biotech indexes or healthcare-focused ETFs for exposure to the biopharma sector.

Biopharma Bounce-Back: From Policy Pains To Profitable Plains

ARK Genomic Revolution Multi-Sector ETF

VanEck Vectors Biotech ETF

Look if it's the right time to invest in biotech ETFs to help diversify your portfolio.

Is Now the Right Time to Embrace Biotech ETFs?

ARKG: Outperforming XBI, Reasonably Valued With Technical Upside Potential In 2H

Artificial Intelligence stands to revolutionize drug discovery and manufacturing in the biotech industry, promising faster, cost-effective processes, which could greatly benefit biotech investors. The SPDR S&P Biotech ETF, an equal-weighted fund with broad industry exposure, presents an attractive investment vehicle to leverage these AI-driven changes. Despite recent downturns in the biotech sector and XBI's specific exposure to smaller, speculative biotech firms, long-term trends and AI advancements suggest a strong rebound.

XBI: A Vehicle For The Transformative Benefits Of Artificial Intelligence Within Biotechnology

Subscribers to  Chart of the Week  received this commentary on Sunday, June 18.

Biotech Stocks Ripe for a Short Squeeze

Subscribers to  Chart of the Week  received this commentary on Sunday, June 11.

Buy This ETF Before June Runs Out

ACADIA Pharma

Agios Pharmaceuticals

BioMarin Pharmaceutical

CareDx

Exact Sciences

Exelixis

First Trust NYSE Arca Biotechnology Index Fund

FibroGen

Ionis Pharma

Madrigal Pharmaceuticals

Moderna

Pacific Biosciences of California

Regeneron Pharmaceuticals

Seagen

Teladoc

TG Therapeutics

Here are the five best biotech ETFs to invest in right now.

Investing in Biotech ETFs

Several ETFs exist offering investors concentrated biotech exposure that varies in stock selection and weighting schemes. While all of the choices exhibit 90%+ exposure to biotech stocks, only XBI is a true pure-play at nearly 100%.

XBI: A Pure Play Biotech ETF In Need Of A Hedge

Breakwave Tanker Shipping ETF

VanEck Vectors Gold Miners ETF

VanEck Junior Gold Miners ETF

Quadratic Interest Rate Volatility and Inflation ETF

SPDR S&P Bank ETF

Invesco KBW Bank ETF

SPDR S&P Regional Banking ETF

AllianzIM US Large Cap Buffer10 May ETF

AllianzIM US Large Cap Buffer20 May ETF

Aberdeen Standard Physical Silver Shares ETF

SPDR Portfolio Developed World ex-US ETF

SPDR S&P 500 ETF Trust

United States Natural Gas Fund LP

United States Oil Fund LP

Hello! In this week's ETF Wrap, I caught up with The ETF Store's Nate Geraci and State Street's Matthew Bartolini on flows as investors worry about a potential recession and try to discern the Fed's next policy moves.

ETF flows point to ‘skittish' investors as it's ‘a little unwieldy out there' after Fed rate hikes

Global X Robotics & Artificial Intelligence ETF

First Trust Dorsey Wright Focus 5 ETF

iShares Robotics & Artificial Intelligence Multisector ETF

JPMorgan US Momentum Factor ETF

Direxion NASDAQ-100 Equal Weighted Index Shares

iShares MSCI USA Quality Factor ETF

Alpha Architec U.S. Quantitative Value ETF 

ROBO Global Robotics and Automation ETF

Invesco S&P 500 Pure Value ETF

ALPS Sector Dividend Dogs ETF

Invesco S&P 500 Quality ETF

Communication Services Select Sector SPDR Fund

This week, the VettaFi Voices gather around the water cooler and talk smart beta and equal weight ETFs.

VettaFi Voices On: Smart Beta and Equal-Weight ETFs

We believe the M&A wave in the biotech sector presents a prime opportunity for investors to profit from the rising valuations of small and mid-cap firms in SPDR® S&P Biotech ETF. Big pharma companies, facing patent cliffs and pricing pressures, drive M&A activity, with substantial acquisitions expected from major industry players.

XBI: Uncorrelated Growth Capitalizing On The M&A Tidal Wave In Pharma

ALPS Medical Breakthroughs ETF

Biotech comes with a great many positive externalities for society, and can be a big positive for portfolios right now.

Biotech ETFs' Performance Deserves A Look

A discerning approach is warranted even as Merck lifts the sector with a deal for a company without any approved products.

How to Tell Biotech's Likely Winners From Losers

BeiGene

Coherus BioSciences

Amicus Therapeutics

Novartis

China's pandemic-era travel restrictions paused approvals on some new drugs. The end of Zero Covid means the pipeline will reopen.

The FDA Is Resuming Drug Lab Inspections in China. These Biotechs Could Benefit.

Biotech names tend to have some of the best upsides for a well-informed investor. For a majority of us understanding the industry is no easy task and many individual biotech names can be fraught with uncertainty.

XBI: Derisking Biotech Exposure Through An ETF

iShares S&P Small-Cap 600 Value ETF

Invesco KBW Premium Yield Equity REIT ETF

SPDR S&P Dividend ETF

Share prices appear unaffected as passive ETF and mutual fund stakes hit 19%, analysis says.

Passive Funds' Ownership of US Stocks Soars

XBI sits 58% below its all-time high. Yet I still don't think it is a good investment here. There are too many risk factors for the smaller biotech stocks this ETF owns, and tighter lending conditions will only complicate things.

XBI: Underperformance Of Small Cap Biotech Likely To Continue

Virtus LifeSci Biotech Clinical Trials ETF

iShares U.S. Pharmaceuticals ETF

iShares U.S. Healthcare Providers ETF

iShares U.S. Medical Devices ETF

iShares U.S. Healthcare ETF

Invesco Dynamic Biotechnology & Genome ETF

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

Invesco S&P 500 Equal Weight Health Care ETF

Vanguard Health Care ETF

SPDR S&P Pharmaceuticals ETF

How SVB's collapse is impacting healthcare startups. Pfizer to buy Seagen for $43B.

The Fall Of SVB: What It Means For Healthcare Startups

Loncar Cancer Immunotherapy ETF

Global X Genomics & Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector

Here are some of the biggest movers on Monday with banks firmly in focus after federal regulators stepped into protect deposits at fallen bank SVB.

Regional banks pace decliners, as biotech deals lift Seagen and Provention Bio

Shares of the SPDR S&P Biotech ETF XBI tumbled toward a six-month low last week, closing at $75.66 on Friday, over concerns about biotech exposure to Silicon Valley Bank, which is owned by SVB Financial Group SIVB.

Biotech ETF nears a six-month low

Rising interest rates taking steam from rally that powered in IBB and XBI. 

The Recent Bullish Trend in IBB, XBI Looks Shaky

Biogen

Horizon Pharma

The latest earnings from some of the big biotech players came in at mixed this reporting season.

How Are Biotech ETFs Reacting to Q4 Earnings Releases?

News for SPDR S&P Biotech ETF ETF (XBI)